Overview
Cyprotex provides specialized ADME-Tox services, including in vitro screening, mechanistic toxicology, high content 3D tissue analysis, and pharmacokinetic predictions via Cloe PK. They support drug discovery from early stages to regulatory submission with high-throughput assays, immunotoxicology, gene therapy capabilities, and AI-driven data generation. As part of Evotec, Cyprotex delivers rapid turnaround times of 5-10 working days for standard screens using validated in vitro and in silico methods.
Frequently asked questions
- What ADME-Tox capabilities does Cyprotex offer?
- Cyprotex offers in vitro ADME screening, mechanistic toxicology, high content 3D tissue analysis, mitochondrial toxicity, immunotoxicology, and Cloe PK for pharmacokinetic predictions across drug discovery and development.
- What is the typical turnaround time for Cyprotex services?
- Data for most standard screens is returned within 5-10 working days, supporting rapid decision-making in drug discovery.
- Does Cyprotex support regulatory studies and advanced modalities?
- Yes, Cyprotex provides regulatory in vitro ADME, DDI studies, gene therapy capabilities, biologics, oligonucleotides, and AI-optimized datasets from early discovery to preclinical and clinical stages.